Skip to main content
Infection and Drug Resistance logoLink to Infection and Drug Resistance
. 2026 Nov 5;19:652286. doi: 10.2147/IDR.S652286

Beyond the Reach of Standard Prophylaxis: Mycoplasma hominis and Ureaplasma Spp. in Postoperative Urological, Andrological and Renal Transplant Infections

Dung Mai Ba Tien 1,2,*, Trung Nguyen Hoang 3,*, Minh Tong Duc 3, Outha Thavixay 4, Thanh Bui Duc 5,✉
PMCID: PMC13746830  PMID: 43005827

Abstract

Genital mollicutes, namely Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum, colonize the lower urogenital tract of a substantial minority of healthy adults yet are rarely considered in postoperative urological, andrological or renal transplant infection. This narrative review examines the diagnostic and prophylactic gap they create. Their lack of a cell wall makes Gram staining uninformative and confers intrinsic resistance to beta-lactams and glycopeptides. Routine microbiology also has limited sensitivity: Ureaplasma spp. generally require specialized culture or molecular detection, whereas M. hominis may grow slowly on enriched routine media but is easily overlooked. Reported disease ranges from sterile pyuria and graft pyelonephritis to perinephric or prostatic abscess, encrusting uropathy, recurrent struvite calculi and hyperammonemia syndrome. Commonly recommended perioperative agents provide little or no reliable activity against these organisms. Acquired resistance is strongly regional: among Ureaplasma isolates from North America and Germany, reported resistance to several key agents remains below 8%, whereas Vietnamese surveillance found ciprofloxacin resistance of 76.0% in U. urealyticum and 88.0% in M. hominis; doxycycline and josamycin retained greater activity but were not uniformly active. We propose five pragmatic clinical triggers, compartment-directed sampling and region-aware empiric management while emphasizing that these recommendations rest predominantly on case-level evidence. Prospective surgical studies are needed to define incidence, diagnostic thresholds and the role of screening.

Keywords: Mycoplasma hominis, Ureaplasma urealyticum, postoperative infection, urological surgery, antimicrobial resistance, culture-negative infection

Introduction

Many urological and andrological interventions traverse colonized mucosa or manipulate sites that may harbor microorganisms. Endoscopic procedures traverse the urethra, stone surgery may manipulate colonized or infected calculi, transplantation reconstructs the urinary tract in a pharmacologically immunosuppressed host, and prosthetic implantation places a foreign body adjacent to genital mucosa. Perioperative antimicrobial prophylaxis is intended to reduce procedure-related infection, yet postoperative urinary tract infection after transurethral procedures remains a recognized complication despite prophylaxis.1 A proportion of that residual burden is attributable to antimicrobial resistance among organisms that prophylaxis is designed to cover. We argue here that some otherwise unexplained infections may instead involve organisms for which standard prophylaxis provides no reliable coverage.

Global antimicrobial-resistance prioritization depends on surveillance systems capable of generating robust burden and resistance estimates. The 2024 World Health Organization Bacterial Priority Pathogens List scored 24 antibiotic-resistant pathogens across eight criteria including mortality, incidence, ten-year resistance trends and treatability, and placed carbapenem-resistant Gram-negative organisms and rifampicin-resistant Mycobacterium tuberculosis in the highest-priority group.2,3 Genital mollicutes appear on neither the 2017 nor the 2024 list. Their absence should not be interpreted as evidence of clinical irrelevance: burden is more difficult to quantify for organisms that are not reliably captured by routine diagnostic workflows.

Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum colonize the lower urogenital tract of a substantial minority of healthy adults. Colonization with M. hominis has been reported across a wide range, from 21% to 53%,4 and Ureaplasma spp. have been reported to colonize 25% to 40% of adults.5 In a Chinese series of 135,263 outpatients, the combined positivity rate for Ureaplasma spp. and M. hominis was 38.1%.6 A non-trivial proportion of patients may therefore enter urological procedures with pre-existing lower-tract colonization, yet genital mollicutes may not be routinely considered in the differential diagnosis of postoperative infection.

This review advances three propositions. First, routine microbiological work-up does not reliably detect genital mollicutes, so postoperative infections they cause may be misattributed or left unexplained. Second, commonly recommended perioperative prophylaxis regimens provide little or no reliable activity against both genera, a gap driven largely by intrinsic biology rather than by an epidemiological resistance rate alone. Third, acquired resistance among the remaining therapeutic options is geographically heterogeneous, with particularly high resistance to older fluoroquinolones reported in parts of East and Southeast Asia.

The scope of this review is limited to M. hominis, U. urealyticum and U. parvum in adults undergoing urological, andrological or renal transplant procedures. We do not address Mycoplasma genitalium, which is a sexually transmitted urethritis pathogen with a distinct epidemiology and a separate body of resistance literature, nor do we address neonatal or obstetric mollicute disease. We describe in turn the biological features that underlie both invisibility and resistance, the diagnostic failure they produce, the clinical spectrum reported after urogenital intervention, the structural gap in prophylaxis, the geography of acquired resistance, and a proposed pathway for clinical suspicion and testing.

Literature Search Strategy

This article is a narrative review. It was designed to address a clinically oriented question rather than to estimate incidence or to pool effect sizes: what is currently known about M. hominis, U. urealyticum and U. parvum as causes of infection after urological, andrological and renal transplant procedures, how these organisms are detected, and how their intrinsic and acquired antimicrobial resistance affects perioperative prophylaxis and empiric treatment.

Literature searches were performed between June and August 2026 in PubMed/MEDLINE, without restriction on publication date. Search terms combined organism names (“Mycoplasma hominis”, “Metamycoplasma hominis”, “Ureaplasma urealyticum”, “Ureaplasma parvum”, “genital mycoplasmas” and “mollicutes”) with clinical terms (“postoperative”, “surgical site infection”, “urological surgery”, “kidney transplantation”, “prostatic abscess”, “urolithiasis”, “struvite”, “encrusted pyelitis” and “hyperammonemia”) and with terms related to diagnosis and resistance (“culture-negative”, “polymerase chain reaction”, “metagenomic sequencing”, “antimicrobial susceptibility” and “antimicrobial resistance”). The reference lists of relevant articles were hand-searched to identify additional reports. Current urological prophylaxis guidance from the European Association of Urology, the American Urological Association and the German interdisciplinary AWMF S3 guideline was reviewed directly, and ClinicalTrials.gov and the National Institutes of Health RePORTER database were searched in August 2026 for registered or funded studies.

Articles were eligible if they were published in English and reported one or more of the following: infection caused by these organisms in adults after urological, andrological or renal transplant procedures; postoperative or device-associated mollicute infection in other surgical settings, where informative for biological plausibility or diagnostic approach; diagnostic methods for these organisms; antimicrobial susceptibility or resistance mechanisms of urogenital isolates, with priority given to recent and larger surveillance series and to systematic reviews and meta-analyses; or urological prophylaxis guidance. Case reports, case series, observational studies, surveillance studies, experimental studies, systematic reviews, meta-analyses and guidelines were eligible. Studies of Mycoplasma genitalium, neonatal or obstetric mollicute disease and veterinary infection, and conference abstracts without a full-text publication, were excluded.

Two authors (DMBT and TNH) screened titles, abstracts and full texts and extracted the relevant clinical, microbiological and susceptibility data, and a third author (MTD) verified the extracted data and references against the original publications. Consistent with the narrative design, no formal risk-of-bias assessment, study-selection flow diagram or quantitative synthesis was undertaken, and the review is not intended to provide a systematic estimate of incidence.

Cell-Wall Deficiency and Genome Reduction Explain Key Diagnostic and Therapeutic Features

A note on nomenclature is required before proceeding, because it affects literature retrieval. A genome-based phylogenetic revision of the phylum proposed the order Mycoplasmoidales containing the new families Mycoplasmoidaceae and Metamycoplasmataceae, under which M. hominis was reclassified as Metamycoplasma hominis while Ureaplasma was placed in the Mycoplasmoidaceae.7 Both names appear in the recent literature and both should be used when searching. We retain the traditional binomials throughout for consistency with the clinical sources cited.

Genital mollicutes are cell-wall-deficient bacteria with highly reduced genomes and exacting nutritional requirements.8,9 The absence of peptidoglycan makes them uninformative on Gram staining and intrinsically resistant to beta-lactams and glycopeptides.10 Genome reduction contributes to fastidious growth and dependence on host-derived nutrients, while the absence of de novo folate synthesis explains the inactivity of sulfonamides and trimethoprim.9,10 These are related but distinct biological mechanisms; cell-wall absence alone does not explain every diagnostic or resistance feature. The features relevant to postoperative disease are summarized in Table 1.

Table 1.

Biological Features of Genital Mollicutes and Their Relevance to the Operating Surgeon

Feature Mycoplasma hominis Ureaplasma Urealyticum/U. parvum Implication for the Operating Surgeon
Cell wall Absent Absent Not visualized on Gram stain; beta-lactams and glycopeptides have no target9,11
Growth on routine media May grow slowly on enriched blood/chocolate agar; easily overlooked Generally not recovered on routine bacteriological media; specialized media or molecular methods required Routine urine/wound workflows have limited sensitivity; a negative routine culture does not exclude mollicutes11,12
Genome and metabolism Reduced genome; obligate extracellular parasite dependent on host sterols and nucleotides Reduced genome; same dependence Fastidious growth reflects genome reduction and nutritional dependence; small M. hominis colonies may be missed after prolonged incubation8,9
De novo folate synthesis Absent Absent Sulfonamides and trimethoprim are inactive9,11
Ammonia-generating enzyme Arginine dihydrolase Urease Urease-mediated urinary alkalinization promotes struvite formation; the strongest causal evidence for hyperammonemia is from disseminated Ureaplasma infection11,13
Additional intrinsic resistance 14- and 15-membered macrolides Lincosamides Species identification is important because intrinsic resistance differs between the two genera11,14
Biofilm formation Not specifically quantified in the clinical isolates summarized here 9 of 11 clinical isolates (82%), with reduced susceptibility in the sessile state Ureaplasma biofilm formation supports biological plausibility for device-associated persistence, but direct evidence in urological prostheses is lacking12,15
Urogenital colonization in adults 21% to 53% 25% to 40% Genital mollicute colonization may therefore be present before urological intervention4,5

Both genera can generate ammonia, but by different metabolic routes. Ureaplasma spp. possess a potent urease that hydrolyzes urea, whereas M. hominis derives energy from arginine through the arginine dihydrolase pathway.11 Locally within the urinary tract, urease-mediated alkalinization promotes precipitation of struvite and calcium phosphate, placing Ureaplasma among the recognized agents of infection stones and encrusting uropathy. Systemically, ammonia-generating metabolism has been implicated in non-cirrhotic hyperammonemia syndrome in immunosuppressed hosts; the strongest causal evidence is for disseminated Ureaplasma infection, as discussed below. These local and systemic consequences are documented after urological and transplant procedures.

Biofilm formation is less widely appreciated but is potentially relevant to implant surgery. Among eleven clinical Ureaplasma isolates recovered from men with urethritis or chronic prostatitis, nine (82%) formed biofilms in vitro, and sessile growth was associated with reduced susceptibility to several antimicrobial agents.15 These findings establish a biofilm-forming capacity in Ureaplasma and provide biological plausibility for persistence on foreign material. A systematic review of thoracic surgery and transplantation also documents postoperative and device-related infections caused by genital mollicutes.12 Direct evidence for mollicute infection of urological prostheses, however, remains lacking.

Because genital mollicutes may already colonize the lower urogenital tract, interventions that breach the mucosal barrier, including endoscopic instrumentation, catheterization, urethral reconstruction and ureteric anastomosis, provide a biologically plausible route of translocation from a colonized surface to normally sterile tissue, the operative bed or implanted material. Endogenous translocation is therefore one plausible mechanism and does not require a breach of theater asepsis. In transplantation, two additional routes are established: transmission within the donor organ and dissemination from a colonized recipient urinary tract under immunosuppression. Immunosuppression may facilitate progression from colonization to invasive disease and dissemination.

Taken together, these properties predict a diagnostic problem before they predict a clinical one. An organism that is not visualized on Gram stain, is not reliably recovered by routine microbiology and is unaffected by commonly used beta-lactam prophylaxis can, when it causes postoperative infection, present as a culture-negative or culture-unrevealing process that fails to respond to standard empiric therapy. That recurring pattern is the subject of the following section.

Routine Microbiology Can Miss Mollicutes, and Diagnostic Delay is Where Harm Accumulates

The biological features described above translate into a diagnostic blind spot. Gram staining is uninformative for both genera.10,11 Ureaplasma spp. generally require specialized media or molecular detection, whereas M. hominis may grow on enriched blood- or chocolate-based media after prolonged incubation but forms pinpoint colonies that can easily be overlooked.12 Thus, standard urine or wound culture workflows have limited sensitivity for genital mollicutes. When targeted testing is not requested, a negative routine result may be falsely reassuring, particularly when the patient is not improving on antimicrobial therapy that lacks anti-mollicute activity.

A recurring clinical pattern across reported cases includes purulent material or a persistent postoperative collection with negative or unrevealing Gram stain and routine culture, failure to improve on standard empiric beta-lactam therapy, and, in urological patients, sterile pyuria. M. hominis should therefore be considered when culture-negative purulent discharge follows surgery or when an apparent postoperative infection does not respond as expected.16 In a series of ten renal allograft recipients who presented with sterile leukocyturia and positive Ureaplasma or Mycoplasma urine cultures, five were symptomatic with dysuria or graft-site pain and three developed biopsy-proven acute graft pyelonephritis with graft dysfunction, one of whom also had a renal abscess on magnetic resonance imaging.17 Similar culture-negative postoperative patterns have been reported after head trauma with neurosurgical management and after cardiac surgery, supporting a diagnostic problem that is not organ-specific.16,18

The delay generated by this blind spot can be clinically consequential, and morbidity may accrue while the diagnosis remains unrecognized. In a case series with literature review of 37 patients with M. hominis mediastinitis, 30 (81.1%) were postoperative infections, 15 (40.5%) involved implanted devices and 5 (13.5%) died.19 In a representative case, an aortic valve recipient with culture-negative purulent wound discharge did not respond to sulbactam and ampicillin, developed mediastinitis and pseudoaneurysm rupture requiring re-operation, and was diagnosed only after cultures specifically targeting M. hominis and Ureaplasma spp. were requested.16 In a renal transplant recipient, a perinephric collection persisted despite therapy directed at an initially cultured Enterococcus faecalis; M. hominis was identified only on molecular testing of a repeat aspirate, after which the abscess resolved on moxifloxacin combined with doxycycline.20 A patient with recurrent bilateral struvite calculi underwent eight operations with repeatedly negative conventional cultures before U. urealyticum was recovered from bladder urine, renal pelvic urine and the stone itself.21 Across these examples, diagnosis became possible only after the clinical team deliberately requested testing outside the routine pathway.

Several complementary diagnostic approaches can help close this gap, differing in availability, turnaround time and the information they provide. Specialized culture remains important and, when successful, provides an isolate for phenotypic susceptibility testing; Ureaplasma generally requires specialized media, whereas M. hominis may sometimes be recovered on enriched routine agar if incubation is sufficiently prolonged.11,12 Commercial microdilution kits provide combined detection and semi-quantitative susceptibility testing and are widely available in Asia, but their limitations are discussed later. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry identified all 55 clinical M. hominis isolates to species level in a reference evaluation, with 95% achieving score values of at least 2.000 on duplicate spotting,22 although performance depends on the presence of mollicute spectra in the instrument library. Species-specific quantitative polymerase chain reaction, applied alongside culture and mass spectrometry within a stepwise sampling protocol, has resolved multisite postoperative mollicute infection where routine cultures were uninformative.18 Metagenomic next-generation sequencing has increasingly served as a diagnostic endpoint in refractory culture-negative infection, including M. hominis meningitis after neurosurgery23 and M. hominis peritonitis in a patient receiving continuous ambulatory peritoneal dialysis.24 Standardized criteria for interpreting metagenomic results remain incomplete, particularly for non-sterile specimens and low-abundance reads.25 The relationship between clinical entity and the expected result of each class of test is summarized in Figure 1.

Figure 1.

Urogenital states by compartment and detection status for three test types. Two-part table with 9 columns and 4 rows. Column headers, left to right: Column 1, Compartment; Column 2, Asymptomatic colonization; Column 3, Urethritis after instrumentation; Column 4, Sterile pyuria; Column 5, Graft pyelonephritis; Column 6, Infection stones, encrusting uropathy; Column 7, Surgical site infection, abscess; Column 8, Device-associated infection; Column 9, Disseminated disease, hyperammonemia. Row 1: Compartment. Column 1, Compartment. Columns 2 to 4 grouped under, Colonization, mucosal and lower-tract disease. Columns 5 to 9 grouped under, Deep, device-associated or disseminated disease. Row 2: Detection status. Column 1, Detection status. Column 2, Asymptomatic colonization. Column 3, Urethritis after instrumentation. Column 4, Sterile pyuria. Column 5, Graft pyelonephritis. Column 6, Infection stones, encrusting uropathy. Column 7, Surgical site infection, abscess. Column 8, Device-associated infection. Column 9, Disseminated disease, hyperammonemia. Row 3: Routine urine or wound culture asterisk. Column 2, minus. Column 3, minus. Column 4, minus. Column 5, minus. Column 6, minus. Column 7, minus. Column 8, minus. Column 9, minus. Row 4: Mollicute-specific culture. Column 2, plus. Column 3, plus. Column 4, plus. Column 5, plus. Column 6, plus or minus. Column 7, plus or minus. Column 8, plus or minus. Column 9, plus or minus. Row 5: Species-specific polymerase chain reaction. Column 2, plus. Column 3, plus. Column 4, plus. Column 5, plus. Column 6, plus. Column 7, plus. Column 8, plus. Column 9, plus.

Peri-interventional spectrum of mollicute-associated urogenital states and disease, shown against the corresponding detection pattern. Clinical entities are arranged by depth of tissue involvement, from colonization and mucosal or lower-tract disease on the left to deep, device-associated or disseminated disease on the right; the boundary is placed between sterile pyuria, which is a laboratory finding compatible with colonization or localized lower-tract infection, and graft pyelonephritis, which involves the renal parenchyma. The lower panel indicates the typical detection pattern of routine culture, mollicute-specific culture, and species-specific polymerase chain reaction for each entity. Symbols: +, expected positive; ±, variable, dependent on the compartment sampled; −, usually negative. *Usually negative rather than invariably so: Ureaplasma spp. are not recovered by routine bacteriological culture, whereas M. hominis may grow slowly on some routine media and is easily overlooked.

Abbreviation: PCR, polymerase chain reaction.

Specimen selection is as consequential as method selection and is an area in which urological practice can change immediately. Midstream urine may be uninformative for deep or device-associated disease. Evidence from stone surgery shows that stone culture and renal pelvic urine culture are more reliable than midstream urine culture for identifying causative organisms after percutaneous nephrolithotomy, and urease-producing organisms that are poorly recovered by standard culture are one explanation for apparently culture-negative infection.26 For suspected mollicute disease, we therefore recommend sampling the affected compartment directly whenever feasible: abscess aspirate, operative tissue, renal pelvic urine, the calculus itself or explanted device material.

One caution must accompany any recommendation to test more widely. Detection is not equivalent to infection. Genital mollicutes colonize the lower urogenital tract of a substantial proportion of sexually active adults, and no validated quantitative threshold currently distinguishes colonization from invasive disease in the postoperative setting. The clinical value of a positive result therefore rests on the compartment sampled and on the presence of the clinical triad described above, an evidentiary limitation we return to in our discussion of research gaps.

A Recognizable Spectrum of Postoperative Urogenital Disease Has Emerged from Scattered Reports

The evidence base for mollicute infection after urological and andrological intervention consists almost entirely of case reports and small case series. Read individually, each may appear exceptional; read together, they suggest a coherent spectrum with recurring risk factors and a recurring diagnostic trajectory. Evidence outside urology provides additional biological context: among 37 reported patients with M. hominis mediastinitis, 30 (81.1%) were postoperative infections, 15 (40.5%) involved implanted devices and 5 (13.5%) died.19 The spectrum is shown in Figure 1, the reported urogenital cases are summarized in Table 2, and four recurring patterns are described below.

Table 2.

Reported Urogenital and Device-Associated Mollicute Findings Relevant to Perioperative Practice

Clinical Setting Organism Presentation Diagnostic Route Management and Outcome Ref
Renal allograft, case series (n = 10) Ureaplasma spp. and M. hominis Sterile leukocyturia; 5 symptomatic; 3 with biopsy-proven graft pyelonephritis, 1 with renal abscess Routine culture negative; diagnosed on mollicute-specific urine culture All treated successfully [17]
Renal allograft, perinephric abscess M. hominis Collection persisting after therapy directed at co-isolated Enterococcus faecalis Routine culture misleading; molecular testing of repeat aspirate Moxifloxacin with doxycycline; complete resolution [20]
Renal allograft, encrusted pyelitis U. urealyticum Graft pain, rising creatinine, sterile pyuria, alkaline urine, calyceal calcium deposits Conventional urine culture negative Doxycycline with urinary acidification and removal of encrustations [27]
Kidney transplant, hyperammonemia syndrome M. hominis Encephalopathy; ammonia 511 micromol/L; urinary leak from necrotic transplant ureter Cultures negative; serum and urine PCR positive Doxycycline with levofloxacin; fatal outcome [28]
Kidney transplant, disseminated disease U. urealyticum, fluoroquinolone-resistant Hyperammonemia syndrome Molecular diagnosis Options limited by resistance [29]
Donor-derived cluster, 1 donor and 4 recipients including kidney M. hominis and Ureaplasma spp. Hyperammonemia syndrome in lung and heart recipients, both fatal Donor urethral discharge cultured for conventional pathogens only Antimicrobials with ammonia scavengers [30]
Recurrent struvite calculi, 8 operations U. urealyticum Rapidly recurrent bilateral infection stones Repeated conventional cultures negative; organism recovered from bladder urine, renal pelvic urine and stone Doxycycline eradicated the organism; urinary pH subsequently normalized; no recurrence for 6 months [21]
Infection stones versus metabolic stones (n = 145 and 247) U. urealyticum 30% versus 13% recovery from voided urine Ureaplasma-specific culture Not applicable [31]
Urinary infection stones (n = 30) U. urealyticum Recovered from midstream urine in 26.7% Ureaplasma-specific culture Not applicable [32]
Prostatic abscess M. hominis Acute urinary retention with large prostatic abscess; fluoroquinolone failure Urine, semen, pus and tissue cultures negative; multiplex PCR of prostatic tissue Transurethral drainage; doxycycline (azithromycin was also administered); clear at 6 months [33]
Robot-assisted laparoscopic radical prostatectomy M. hominis High fever, leukocytosis, elevated C-reactive protein and perineal pain on postoperative day 5 Urine culture submitted on postoperative day 7; M. hominis detected 1 week later Cefmetazole ineffective; switched to a quinolone with rapid clinical and laboratory improvement [34]
Chronic prostatitis (n = 597) U. urealyticum High counts in expressed prostatic secretions in 13.7% Quantitative localization cultures Not applicable [35]
Extra-urological reports supporting biological plausibility
Prosthetic knee, post-arthroplasty M. hominis and U. urealyticum Surgical site infection on day 8; urinary catheter removed at 48 hours Failure of vancomycin, ciprofloxacin and linezolid; directed testing Directed therapy [36]
Prosthetic valve endocarditis, at least 13 reported cases M. hominis Onset usually within 1 year of valve replacement Blood cultures negative Varied [4]
Mediastinitis, 37 pooled cases M. hominis 81.1% postoperative, 40.5% device-associated, 13.5% mortality Cultures negative; metagenomic next-generation sequencing Varied [19]

Abbreviation: PCR, polymerase chain reaction.

Kidney Transplantation is the Setting in Which the Pattern is Best Documented

Renal allograft recipients combine every predisposing factor: instrumentation of the urinary tract, ureteric anastomosis, indwelling stents and catheters, and pharmacological immunosuppression. In a series of ten allograft recipients with positive Ureaplasma or Mycoplasma urine cultures presenting with sterile leukocyturia, five remained asymptomatic while five had dysuria or graft-site pain; three developed biopsy-proven acute graft pyelonephritis with graft dysfunction, one with an accompanying renal abscess on magnetic resonance imaging, and all were successfully treated.17 A perinephric abscess in a transplant recipient was initially attributed to Enterococcus faecalis recovered from the first aspirate and treated with ampicillin and sulbactam; the collection persisted despite prolonged therapy, and M. hominis was identified by molecular testing only on a repeat aspirate, after which the abscess resolved completely on moxifloxacin with doxycycline.20 Encrusted pyelitis attributable to U. urealyticum has been described in a graft recipient who presented with graft pain, rising creatinine, sterile pyuria on conventional culture, microscopic hematuria and alkaline urine, with calcium deposits demonstrated within the mid and lower pole calyces.27 Two features recur in all three reports: conventional urine culture was negative or misleading, and the correct diagnosis followed a deliberate decision to look for a different class of organism.

Hyperammonemia Syndrome is a Severe Manifestation and a Recognized Donor-Derived Risk

Ureaplasma spp. have a well-established mechanistic link to hyperammonemia through urease-mediated ammonia generation, and disseminated Ureaplasma infection has been demonstrated as a cause of fatal hyperammonemia in humans.13 M. hominis also generates ammonia, through arginine metabolism. It has been detected in severe post-transplant infections, including mixed mollicute infections associated with hyperammonemia, although the contribution of each organism in mixed infections may be difficult to separate. Fatal hyperammonemia syndrome has also been reported outside the lung-transplant population. In one report of two such patients, the first was receiving salvage chemotherapy for a hematological malignancy; serum ammonia reached 1,643 micromol/L, and U. urealyticum was detected by serum polymerase chain reaction after death. The second was a deceased-donor kidney recipient whose course was complicated by a urinary leak from a necrotic transplant ureter; serum ammonia reached 511 micromol/L, and M. hominis was detected by polymerase chain reaction in both serum and urine.28 A further kidney recipient developed hyperammonemia syndrome from disseminated, fluoroquinolone-resistant U. urealyticum.29 Donor-derived transmission has also been demonstrated directly. In one cluster, a single deceased donor transmitted M. hominis and/or Ureaplasma spp. to four recipients: the lung and heart recipients developed hyperammonemia syndrome and died, and screening samples from the liver recipient and one kidney recipient were culture positive. The donor had urethral discharge that was cultured for conventional pathogens but not tested for mollicutes.30 This cluster illustrates how the same diagnostic blind spot can operate during donor assessment.

Ureaplasma-Associated Infection Stones May Recur When the Organism is Not Identified

The urease of Ureaplasma spp. alkalinizes urine and drives struvite crystallization, which places these organisms among the causes of infection stones and, critically, among the causes of stone recurrence after otherwise successful surgery. Experimental evidence supports a causal role: incubation of U. urealyticum in synthetic urine produces alkalinization and crystallization of struvite and calcium phosphate, and inoculation of the organism into rat bladders generates struvite stones in 84% of animals. Clinical observations are consistent with these experimental findings. In patients operated on for renal stones, U. urealyticum was cultured from voided urine in 43 of 145 patients (30%) with infection stones compared with 31 of 247 (13%) with metabolic stones (p less than 0.001).31 In a separate series of 30 patients with urinary infection stones, U. urealyticum was recovered from midstream urine in 26.7%.32 A more recent quantitative study in men with urolithiasis detected urogenital mycoplasmas more frequently in the stone group than in controls (38.0% versus 23.3%, p = 0.0552), although the authors concluded that further work is needed to establish the significance of quantitative detection.37 The clinical consequence is illustrated most starkly by a patient who underwent eight operations for recurrent bilateral struvite calculi with repeatedly negative conventional cultures. U. urealyticum was eventually recovered from bladder urine, renal pelvic urine and the stone at the seventh operation. After doxycycline eradicated the organism, the persistently alkaline urinary pH and the ammonium loading test returned to normal, consistent with removal of the source of urease activity rather than a direct effect of the antibiotic on urinary pH; no stone recurred for six months, until the infection returned.21 This also explains why stone and renal pelvic urine culture outperform midstream urine culture after percutaneous nephrolithotomy, and why urease-producing organisms that do not grow on standard media are a recognized explanation for negative culture in this setting.26

Lower Tract and Device-Associated Disease is Plausible but Remains Poorly Documented

Mollicutes have long been investigated as agents of male lower genital tract inflammation. U. urealyticum was recovered in high numbers from expressed prostatic secretions or post-massage urine in 82 of 597 men (13.7%) with chronic prostatitis in a classical localization study.35 More relevant to the surgical reader is the demonstration that these organisms can produce frank suppuration requiring intervention: in a reported prostatic abscess, empiric fluoroquinolone therapy failed, urine and semen cultures showed no growth, and culture of pus and of tissue scrapings from the abscess cavity likewise yielded no bacterial growth, with multiplex polymerase chain reaction of the prostatic tissue establishing M. hominis as the pathogen; the patient was managed by transurethral drainage with azithromycin and doxycycline and remained clear at six months.33

For implanted urogenital devices, the evidence remains indirect. In our targeted literature search we found no dedicated series of penile prosthesis or artificial urinary sphincter infection attributable to genital mollicutes. This absence should not be interpreted as proof that such infections do not occur, because routine processing of explanted devices may not reliably detect these organisms. Evidence from other implant settings supports biological plausibility: M. hominis and U. urealyticum were identified in a prosthetic-joint infection after knee arthroplasty,36 at least 13 cases of M. hominis endocarditis have been reported after valve surgery,4 and 40.5% of reported M. hominis mediastinitis cases involved implanted devices.19 Urological implants are placed through or adjacent to a potentially colonized field; under-ascertainment may therefore contribute to the absence of reports, but the true incidence is unknown. We regard this as an important and testable research gap.

Common Perioperative Prophylaxis Regimens Provide No Reliable Coverage for Genital Mollicutes

Contemporary perioperative prophylaxis in urology is increasingly risk-adapted and stewardship-oriented. The 2026 European Association of Urology guideline recommends prophylaxis for ureteroscopy, a single preoperative dose for percutaneous nephrolithotomy, prophylaxis for transurethral resection of the prostate, and prophylaxis for high-risk patients undergoing transurethral resection of the bladder. Its table of possible regimens lists trimethoprim, trimethoprim with sulfamethoxazole, a second- or third-generation cephalosporin (designated group 2 or 3 in the guideline), or an aminopenicillin combined with a beta-lactamase inhibitor, and the panel emphasizes that these are possible choices rather than procedure-specific antimicrobial recommendations.38 The American Urological Association Best Practice Statement likewise emphasizes single-dose, procedure- and risk-adapted prophylaxis, with trimethoprim-sulfamethoxazole or a first- or second-generation cephalosporin among the commonly used first-line options.1 For prostatectomy and nephrectomy, the EAU considers the evidence insufficient to recommend either for or against prophylaxis, whereas the 2026 German interdisciplinary AWMF S3 guideline supports a single pre-incision dose for major urological procedures: typically a second-generation cephalosporin or an aminopenicillin with a beta-lactamase inhibitor for radical prostatectomy, and a second- or third-generation cephalosporin combined with metronidazole, or an aminopenicillin with a beta-lactamase inhibitor, for radical cystectomy.39

When these commonly recommended agents are mapped onto the intrinsic biology of genital mollicutes, dependable cross-species coverage is absent. The lack of a cell wall confers intrinsic resistance to beta-lactams and glycopeptides, while the absence of de novo folate synthesis renders sulfonamides and trimethoprim inactive.10 Species-specific intrinsic resistance further complicates alternative choices: Ureaplasma spp. are intrinsically resistant to lincosamides, whereas M. hominis is intrinsically resistant to 14- and 15-membered macrolides.14,40 Although some perioperative regimens contain additional agents such as aminoglycosides, they should not be assumed to provide dependable stand-alone coverage for both genital mollicute genera. The practical point is therefore not that every prophylactic drug is universally inactive, but that standard prophylaxis is not designed to provide reliable coverage of both M. hominis and Ureaplasma spp.

Fluoroquinolones are the principal class with cross-species anti-mollicute activity that has historically featured in some urological prophylaxis protocols, but their routine role has diminished because of stewardship, safety concerns and changing guideline recommendations.38 In settings where fluoroquinolones remain in use, regional resistance is now a second limitation: older agents such as ciprofloxacin and ofloxacin have lost much of their in vitro activity in several Asian surveillance series, whereas susceptibility to newer fluoroquinolones is better preserved.

The distinction between intrinsic and acquired resistance matters because only one of them can be modified. Acquired resistance, such as fluoroquinolone resistance in Ureaplasma spp., varies between regions and over time; it can therefore be tracked with local antibiograms and addressed through antimicrobial stewardship. Intrinsic resistance, such as the inactivity of beta-lactams against all genital mollicutes, cannot be overcome in this way: no increase in dose and no change of cephalosporin generation can act on a cell-wall target that these organisms do not possess. This gap is also partly hidden. Because routine cultures may not detect mollicutes, infections they cause after urological procedures are unlikely to be fully captured in the surveillance data from which prophylaxis policies are derived.

We are not proposing that anti-mollicute agents be added to routine prophylaxis. The incidence of mollicute infection after urological and andrological procedures has never been prospectively measured with systematic mollicute-capable diagnostics, and in the absence of such data the harms of broader prophylaxis would likely outweigh any unproven benefit. The narrower and more defensible implication is that some culture-negative, prophylaxis-breakthrough infections after urogenital instrumentation may involve organisms that standard prophylaxis was never designed to cover, and that these patients require recognition and targeted testing rather than repeated escalation within the same inactive drug classes.

Whether the remaining therapeutic options are still available when such patients are identified is a separate question, and the answer depends heavily on where the patient is treated.

Acquired Resistance is Geographically Heterogeneous, with High Resistance to Older Fluoroquinolones in Parts of Asia

The principal classes used therapeutically across genital mollicutes are tetracyclines, fluoroquinolones and selected macrolides; lincosamide activity is species-specific.14,40,41 Acquired resistance within the active classes is well characterized at the molecular level but is unevenly distributed geographically, and that geography determines whether a nominally active drug remains useful at the point of care. Intrinsic and acquired resistance are summarized together in Table 3.

Table 3.

Intrinsic and Acquired Resistance of Genital Mollicutes with Reported Regional Resistance Rates

Antimicrobial Class Intrinsic Activity Mechanism of Acquired Resistance Reported Resistance Rates Relevance to Perioperative Prophylaxis
Beta-lactams None Not applicable; no peptidoglycan target Not applicable Common prophylaxis option; no activity against mollicutes.11
Glycopeptides None Not applicable; no peptidoglycan target Not applicable No activity.11
Sulfonamides and trimethoprim None No de novo folate synthesis Not applicable Common prophylaxis option; no activity against mollicutes.9,11
Rifampicin None Not applicable Not applicable No activity.11
Lincosamides Active against M. hominis; none against Ureaplasma spp.11 Not characterized Not applicable Species identification required before use
Macrolides, 14- and 15-membered Active against Ureaplasma spp.; none against M. hominis.11,14 23S rRNA domain V (A2058G); rplD (L4); rplV (L22).41,42 Ureaplasma: North America 2.4%; Germany 0%; Vietnam 24.8%. M. hominis: 79.2% erythromycin non-susceptibility, consistent with intrinsic resistance.41,43,44 Avoid 14- and 15-membered macrolides when M. hominis is suspected
Macrolides, 16-membered (josamycin) Active.11 As above.11,41,42 Hangzhou below 5%; Vietnam 6.9% for U. urealyticum and 22.4% for M. hominis.6,44 Active against both genera, but susceptibility is not universal
Tetracyclines Active.11 Tet(M).40,41 North America 6.5%; Germany 4.1%; pooled 14.2% for tetracycline and 5.0% for doxycycline; Vietnam doxycycline 9.6% for U. urealyticum and 25.1% for M. hominis.40,41,43,44 Doxycycline is a pragmatic cross-genus option; consider local susceptibility
Fluoroquinolones Active.11 Quinolone resistance-determining region mutations in parC (S83L, E87K), parE, gyrA and gyrB.41,45,46 North American Ureaplasma: 6.7% levofloxacin resistance; German Ureaplasma: 7.1% fluoroquinolone resistance; pooled: ciprofloxacin 59.8%, ofloxacin 31.2%, moxifloxacin 7.3%, levofloxacin 5.3%; Vietnam ciprofloxacin: 76.0% U. urealyticum, 88.0% M. hominis, 92.2% in coinfection-positive specimens.41,43,44,47 Avoid ciprofloxacin/ofloxacin empirically where local resistance is high; newer agents may retain activity

Notes: Resistance rates are not directly comparable across studies because species composition and susceptibility methods differ. Reference broth microdilution follows Clinical and Laboratory Standards Institute guidance, whereas much Asian surveillance uses commercial microdilution kits.48 For M. hominis, non-susceptibility to 14- and 15-membered macrolides is primarily intrinsic rather than an acquired regional phenotype.11,14 In mixed Ureaplasma/M. hominis cultures, species-specific macrolide susceptibility of the Ureaplasma component cannot be determined reliably10,44.

The best-characterized mechanisms are few and relatively consistent. Macrolide resistance in Ureaplasma is attributed mainly to mutations in domain V of 23S ribosomal RNA and in genes encoding ribosomal proteins L4 and L22, which interfere with binding to the 50S subunit.41,42 The best-established tetracycline-resistance determinant is tet(M), which protects the 30S ribosomal target.40,41 Fluoroquinolone resistance is mediated primarily by mutations in the quinolone resistance-determining regions of topoisomerase IV, encoded by parC and parE, and DNA gyrase, encoded by gyrA and gyrB, in both Ureaplasma spp.45 and M. hominis.46 In a North American Ureaplasma collection, domain-V 23S rRNA or rplD mutations were identified in most erythromycin-resistant isolates; tet(M) was present in all isolates with a tetracycline minimum inhibitory concentration of at least 4 micrograms/mL but absent from many isolates at 2 micrograms/mL; and parC substitutions accounted for most fluoroquinolone-resistant isolates.41 The dissociation between genotype and borderline phenotype means that genotypic testing alone may misclassify some isolates near interpretive breakpoints.

Recent surveillance from North America and Germany suggests that resistance remains relatively low among Ureaplasma isolates in those settings. Among 415 Ureaplasma isolates from the United States and Canada collected between 2012 and 2023, resistance to erythromycin, tetracycline and levofloxacin was 2.4%, 6.5% and 6.7%, respectively, with only 1.0% resistant to two drugs.41 Among 170 Ureaplasma strains isolated in a German university hospital between 2016 and 2019, resistance to macrolides, tetracyclines and fluoroquinolones was 0%, 4.1% and 7.1%, respectively.43 A French series including clinical Ureaplasma spp. and M. hominis isolates from 2010 to 2015 similarly characterized tetracycline and fluoroquinolone resistance in a European setting.49 These data provide useful comparators but should not be generalized to M. hominis or to regions with different antimicrobial exposure and testing methods.

Asian surveillance data differ most clearly for older fluoroquinolones. In a South Korean series of 1,589 culture-positive genital mycoplasma specimens, only 6% and 18.7% of Ureaplasma isolates were susceptible to ofloxacin and ciprofloxacin, respectively, while more than 93% remained susceptible to doxycycline.14 Among 135,263 outpatients tested in Hangzhou, China, josamycin, tetracycline, doxycycline and pristinamycin maintained low overall resistance rates, whereas ofloxacin and ciprofloxacin resistance exceeded 70% and increased over time.6 These observations support regional caution with older fluoroquinolones rather than a class-wide assumption that all fluoroquinolones are ineffective.

Vietnamese surveillance shows the same high-resistance pattern for older fluoroquinolones but comes from a dermatovenereology referral population rather than perioperative patients. In a retrospective analysis of 2,207 genitourinary specimens collected at the National Hospital of Dermatology and Venereology in Hanoi between 2018 and 2022, 654 cultures were positive; U. urealyticum was detected in 97.6%, M. hominis in 28.0%, and 25.5% were coinfection-positive specimens; these proportions overlap because coinfection-positive specimens are counted within both species groups. For U. urealyticum, resistance was 76.0% to ciprofloxacin, 55.8% to ofloxacin, 24.8% to erythromycin, 16.1% to tetracycline, 9.6% to doxycycline and 6.9% to josamycin. M. hominis showed phenotypic non-susceptibility of 88.0% to ciprofloxacin, 77.0% to ofloxacin, 43.7% to tetracycline, 25.1% to doxycycline and 22.4% to josamycin; the 79.2% erythromycin non-susceptibility is consistent with the species’ intrinsic resistance to 14-membered macrolides rather than representing a directly comparable acquired-resistance phenotype. Coinfection-positive specimens showed resistance rates of 92.2% to ciprofloxacin, 80.2% to ofloxacin and 45.5% to tetracycline.44 These data are presented in Figure 2.

Figure 2.

A grouped bar graph showing antimicrobial resistance rates by antibiotic and organism group. A grouped bar graph of isolates resistant percent by antibiotic, with three organism groups in the legend: Ureaplasma urealyticum left parenthesis n equals 638 right parenthesis, Mycoplasma hominis left parenthesis n equals 183 right parenthesis and Coinfection left parenthesis n equals 167 right parenthesis. Vertical axis label: Isolates resistant (percent). Vertical axis range: 0 to 100. Horizontal axis categories are grouped under headings: Tetracyclines, Macrolides, Fluoroquinolones and Streptogramin. The antibiotic labels, left to right, are: Doxycycline, Tetracycline, Azithromycin, Clarithromycin, Erythromycin, Josamycin, Ofloxacin, Ciprofloxacin, Pristinamycin. Data values printed above bars, by antibiotic and organism group. Doxycycline: Ureaplasma urealyticum 9.6 percent; Mycoplasma hominis 25.1 percent; Coinfection 27.5 percent. Tetracycline: Ureaplasma urealyticum 16.1 percent; Mycoplasma hominis 43.7 percent; Coinfection 45.5 percent. Azithromycin: Ureaplasma urealyticum 21.3 percent; Mycoplasma hominis 67.2 percent; Coinfection 67.1 percent. Clarithromycin: Ureaplasma urealyticum 21.3 percent; Mycoplasma hominis 70.5 percent; Coinfection 68.3 percent. Erythromycin: Ureaplasma urealyticum 24.8 percent; Mycoplasma hominis 79.2 percent; Coinfection 77.8 percent. Josamycin: Ureaplasma urealyticum 6.9 percent; Mycoplasma hominis 22.4 percent; Coinfection 24.6 percent. Ofloxacin: Ureaplasma urealyticum 55.8 percent; Mycoplasma hominis 77.0 percent; Coinfection 80.2 percent. Ciprofloxacin: Ureaplasma urealyticum 76.0 percent; Mycoplasma hominis 88.0 percent; Coinfection 92.2 percent. Pristinamycin: Ureaplasma urealyticum 8.3 percent; Mycoplasma hominis 26.2 percent; Coinfection 28.1 percent.

Antimicrobial resistance rates of urogenital mollicutes in Vietnam, 2018 to 2022, among 654 culture-positive specimens. Data are shown for U. urealyticum-positive specimens (n = 638), M. hominis-positive specimens (n = 183), and coinfection-positive specimens (n = 167); coinfection-positive specimens are included in both species-positive groups. Data derived from reference 44. The original study used the Mycoplasma IST2 commercial phenotypic assay and involved a dermatovenereology referral population rather than surgical patients; results from mixed cultures should not be interpreted as species-specific susceptibility of each component.

Pooled estimates support substantial geographic and temporal heterogeneity rather than universal loss of an entire drug class. A meta-analysis of 30 studies from 16 countries reported pooled resistance among urogenital Mycoplasma and Ureaplasma isolates of 59.8% (95% confidence interval 49.6 to 69.1) for ciprofloxacin, 31.2% (95% confidence interval 23 to 40) for ofloxacin, 7.3% for moxifloxacin and 5.3% for levofloxacin, with meta-regression showing significant variation over time and between continents.47 A companion meta-analysis of tetracyclines reported pooled resistance of 14.2% for tetracycline, 5.0% for doxycycline and 11.9% for minocycline, with differing temporal trends across agents.40

Two methodological caveats should temper interpretation of regional figures. First, much Asian surveillance, including the Vietnamese series, relies on commercial microdilution kits that test a fixed panel of agents (doxycycline, tetracycline, azithromycin, clarithromycin, erythromycin, josamycin, ofloxacin, ciprofloxacin and pristinamycin),6,44 rather than on the reference broth microdilution method specified in Clinical and Laboratory Standards Institute guidance, and the two approaches do not always agree.48 Second, M. hominis is intrinsically resistant to 14- and 15-membered macrolides (erythromycin, azithromycin and clarithromycin), so a mixed Ureaplasma/M. hominis culture cannot establish species-specific macrolide susceptibility of the Ureaplasma component.10 Because coinfection was present in approximately one quarter of positive specimens in the Vietnamese series, species-specific Ureaplasma macrolide resistance cannot be inferred from mixed-culture results, and aggregate macrolide estimates from that series should be interpreted cautiously.44

The practical consequence is that older fluoroquinolones, particularly ciprofloxacin and ofloxacin, should not be assumed to provide reliable empiric therapy in settings where local resistance resembles that reported from East and Southeast Asia. Doxycycline and josamycin retained greater activity in the Vietnamese series, but neither was uniformly active, particularly against M. hominis. Empiric choices should therefore be region-aware and revised promptly once species identification and, where available, susceptibility results are obtained.

A Small Set of Clinical Triggers Can Prompt Targeted Diagnosis and Treatment

The practical problem is often not the absence of potentially active treatment once the organism is identified, but the delay before targeted testing is considered. What follows is therefore framed as a pragmatic trigger list rather than a validated diagnostic algorithm. The decisive step is recognition that routine postoperative microbiology may be insufficient in the appropriate clinical context. The proposed pathway is shown in Figure 3.

Figure 3.

A flowchart of triggers, sampling, testing requests, empiric therapy and source control for mollicutes. Flowchart with a top box titled, Clinical triggers after urological andrological or renal transplant intervention. The numbered triggers read: 1. Postoperative collection or discharge, routine culture negative or unrevealing, with no clinical response to appropriate beta-lactam therapy within approximately 48 to 72 hours. 2. Sterile pyuria after instrumentation, or graft pain or graft dysfunction in an allograft recipient. 3. Persistently alkaline urine with rapidly recurrent struvite calculi despite adequate stone clearance. 4. Unexplained encephalopathy or a raised serum ammonia concentration in a transplant recipient. 5. Suspected infection of an implanted urogenital device with negative or unrevealing routine culture. A downward arrow leads to two side by side boxes. Left box title, Sample the affected compartment, with bullets: Abscess aspirate or operative tissue; Renal pelvic urine, not midstream urine; The calculus itself; Explanted device material. Right box title, Name the organisms on the request, with bullets: Mollicute-specific culture; Species-specific PCR; Metagenomic sequencing if the picture remains refractory. A downward arrow leads to a wide box titled, Empiric therapy pending confirmation. Inside are two smaller boxes: left, If M. hominis suspected, with text, Azithromycin and erythromycin intrinsically inactive; clindamycin may be active. Right, If Ureaplasma suspected, with text, Clindamycin inactive; azithromycin may be active, subject to susceptibility. Downward arrows from both boxes lead to a larger box titled, Doxycycline, followed by text, A pragmatic empiric option with activity against both genera; susceptibility is not universal and should be confirmed when possible. To the right of the empiric therapy section is a plus sign with the note, in parallel, not in sequence, pointing to a separate box titled, Source control, listing: Drainage of the collection; Complete stone clearance; Removal of infected foreign material; Urinary acidification for encrusting uropathy.

Proposed clinical trigger and testing pathway for suspected mollicute infection after urological, andrological, or renal transplant intervention. The triggers, including the reassessment window of approximately 48 to 72 hours, are pragmatic clinical prompts rather than validated diagnostic criteria. Empiric therapy is stratified by suspected species because M. hominis is intrinsically resistant to 14- and 15-membered macrolides, whereas Ureaplasma spp. are intrinsically resistant to lincosamides. Doxycycline is presented as a pragmatic cross-genus option rather than the only active single agent; susceptibility is not universal, and local resistance should be considered. Source control should be pursued in parallel with antimicrobial therapy when a drainable collection, calculus, encrustation, or infected foreign material is present. In East and Southeast Asia, ciprofloxacin and ofloxacin should generally not be relied upon empirically where local resistance is high; newer fluoroquinolones may retain activity.

Abbreviation: PCR, polymerase chain reaction.

Five presentations should prompt consideration of genital mollicutes after urogenital intervention. The first is a postoperative collection, wound discharge or abscess with negative or unrevealing Gram stain and routine culture that fails to improve after appropriately dosed beta-lactam therapy over an initial approximately 48–72-hour period; this time window is a pragmatic clinical prompt rather than a validated threshold. The second is sterile pyuria persisting after urinary tract instrumentation, or occurring in a renal allograft recipient with graft pain or unexplained graft dysfunction. The third is persistently alkaline urine with rapidly recurrent struvite calculi despite adequate stone clearance and negative conventional cultures. The fourth is unexplained encephalopathy or a raised serum ammonia concentration in a transplant recipient. The fifth is suspected infection of an implanted urogenital device from which routine culture is negative or unrevealing. These triggers are consistent with reported risk factors for invasive M. hominis infection, including surgery or urinary catheterization, cardiopulmonary disease, immunosuppression and transplantation.50

When one of these triggers is present, two actions follow. The specimen should be taken from the affected compartment rather than relying solely on voided urine: abscess aspirate, operative tissue, renal pelvic urine, the calculus or explanted device material as appropriate.26 The laboratory request should explicitly name the suspected organisms and the desired method. Mollicute-capable culture, species-specific polymerase chain reaction and metagenomic sequencing have different availability and ordering pathways and are not part of routine postoperative bacterial culture in many centers. Where targeted culture and polymerase chain reaction are unavailable and the clinical picture remains refractory, metagenomic sequencing may provide a diagnostic route, with the interpretive caveats noted above.23–25

Empiric therapy pending confirmation should be guided by species-level intrinsic resistance and local epidemiology. M. hominis is intrinsically resistant to 14- and 15-membered macrolides, so azithromycin and erythromycin should not be relied upon when this species is suspected; conversely, Ureaplasma spp. are intrinsically resistant to lincosamides, so clindamycin is not appropriate when Ureaplasma remains possible.14,40 Doxycycline is a pragmatic empiric option with activity against both genera, but susceptibility is not universal: resistance in the Vietnamese series was 9.6% for U. urealyticum, 25.1% for M. hominis and 27.5% among coinfection-positive specimens.44 In regions with high reported resistance, ciprofloxacin and ofloxacin should generally not be relied upon empirically; newer fluoroquinolones have lower pooled resistance estimates, but pooled data cannot substitute for local susceptibility information.47 Regimens reported in the urogenital cases reviewed here included moxifloxacin with doxycycline for perinephric abscess,20 doxycycline for Ureaplasma-associated recurrent calculi,21 and transurethral drainage with doxycycline for prostatic abscess; azithromycin was also administered in that case but should not be interpreted as active therapy against M. hominis.33

Source control should proceed in parallel with antimicrobial therapy whenever a persistent nidus is present. A drainable collection requires drainage, infection stones require complete clearance where feasible, and infected foreign material may require removal. For encrusting uropathy, treatment additionally includes urinary acidification, urological removal of encrustations and prolonged directed antimicrobial therapy.51 Source control is therefore essential when an anatomical nidus is present, but it should not be stated as a requirement for every mollicute infection.

Thoracic-transplant experience demonstrates that pretransplant mollicute screening is feasible, but it does not establish that routine screening improves outcomes. In one lung-transplant program, 105 of 268 recipients underwent polymerase chain reaction testing of pretransplant recipient urine and donor bronchial swabs; 12 (11%) screened positive and received pre-emptive doxycycline, levofloxacin and/or azithromycin for one to twelve weeks.52 Mollicute infections nevertheless occurred, and the retrospective study was not designed to prove a reduction in incidence from screening. Donor-derived transmission to kidney recipients has been demonstrated,30 making renal-transplant screening a defensible research hypothesis rather than a current evidence-based recommendation. Any pre-emptive strategy in kidney transplantation therefore requires prospective evaluation.

The Evidence Base Has Five Specific Gaps, and Each is Addressable

The limitations of the evidence reviewed here are considerable and should be stated plainly. The clinical evidence for mollicute infection after urogenital intervention is dominated by case reports and small series, which are subject to publication bias toward severe and unusual presentations. A 2025 systematic review of Mycoplasma spp. infection after kidney transplantation identified 30 reported episodes across 21 publications, including 18 surgical-site and 6 urinary-tract infections; six graft losses and two deaths were reported, but incidence and prevalence could not be estimated because denominator data were unavailable.53 The resistance data that inform our regional argument derive predominantly from sexual health and dermatovenereology populations rather than from surgical patients, and the two populations may differ in both species distribution and prior antimicrobial exposure. This review is narrative rather than systematic, and it is intended to generate hypotheses and raise clinical awareness rather than to estimate burden. Five specific gaps follow from these limitations.

First, the incidence of mollicute infection after urological and andrological procedures is unknown because no prospective study has systematically applied mollicute-capable diagnostics to a surgical cohort. Isolated procedure-specific reports do exist; for example, postoperative M. hominis infection has been described after robot-assisted laparoscopic radical prostatectomy, but such cases cannot establish incidence.34 A feasible design would enroll consecutive patients undergoing defined procedures, obtain preoperative species-specific testing, and apply targeted testing to postoperative collections or culture-negative infectious syndromes using prespecified criteria. Such a study could distinguish colonization from incident postoperative disease more reliably than retrospective case reports.

Second, no validated quantitative threshold distinguishes colonization from invasive disease in the postoperative setting. Given colonization rates of 21% to 53% for M. hominis4 and 25% to 40% for Ureaplasma species,5 which derive from narrative summaries and vary with population, sampling site and detection method, a qualitative positive result from a mucosal site is of limited interpretive value. A quantitative study in men with urolithiasis found urogenital mycoplasmas more often in the stone group than in controls, 38.0% versus 23.3%, but did not reach conventional significance, and its authors concluded that further work is needed to establish the role of quantitative detection.37 Bacterial load measured in a normally sterile compartment is the most promising discriminator and has not been systematically evaluated.

Third, urogenital implants remain essentially unstudied. Our targeted search identified no dedicated series examining explanted penile prostheses, artificial urinary sphincters or ureteric stents for genital mollicutes. Ureaplasma isolates can form biofilms with reduced susceptibility in the sessile state,15 and device-associated disease is well documented outside urology.19 Sonication of explanted devices combined with species-specific polymerase chain reaction is a testable approach, but the true incidence and clinical significance of positive findings are unknown.

Fourth, donor and recipient screening has been evaluated mainly in thoracic transplantation and has not been shown to reduce mollicute infection in kidney recipients.52 Whether screening can reduce graft pyelonephritis, disseminated infection or hyperammonemia syndrome after kidney transplantation remains untested. Demonstrated donor-derived transmission to solid-organ recipients provides biological justification for studying the question prospectively.30

Fifth, surveillance methodology requires standardization before regional comparisons can be made confidently. Much Asian data derive from commercial kits rather than the reference broth microdilution method,48 and coinfection with M. hominis inflates apparent macrolide resistance in mixed cultures.10 Regional surveillance conducted on surgical rather than sexual health populations, using reference methods, would place the perioperative argument advanced here on a firmer footing.

Our targeted searches of ClinicalTrials.gov and the National Institutes of Health RePORTER, updated in August 2026, identified studies of genital colonization, sexually transmitted infection and thoracic transplantation but did not identify a registered prospective study specifically evaluating mollicute infection after urological or andrological surgery. Because registry indexing and terminology vary, this negative search should be regarded as a time-stamped observation rather than proof that no relevant work exists.

Conclusion

In this review we have argued that genital mollicutes occupy an under-recognized diagnostic and prophylactic gap in the perioperative care of urological, andrological and renal transplant patients. Their lack of a cell wall makes Gram staining uninformative and confers intrinsic resistance to beta-lactams and glycopeptides, while fastidious growth means that routine microbiology may miss them: Ureaplasma generally requires specialized culture or molecular detection, whereas M. hominis can grow slowly on enriched routine media but may be overlooked. Standard prophylaxis therefore does not provide dependable coverage of both genera. Acquired resistance is geographically heterogeneous; in parts of East and Southeast Asia, ciprofloxacin and ofloxacin are unreliable empiric options, while doxycycline, josamycin and newer fluoroquinolones retain greater but incomplete activity. Reported cases describe a spectrum extending from sterile pyuria and recurrent infection stones to graft pyelonephritis, abscess, device-associated infection and hyperammonemia syndrome. The evidence remains dominated by case reports and non-surgical resistance surveillance, so the proposed triggers and treatment pathway should be interpreted as pragmatic, hypothesis-generating guidance rather than validated recommendations. The immediate clinical message is narrower: a negative routine culture in the appropriate postoperative context should prompt consideration of compartment-directed sampling and mollicute-capable testing rather than repeated escalation of empiric beta-lactam therapy.

Funding Statement

No specific funding was received for the preparation of this review.

AI Declaration

During the preparation of this manuscript, the authors used ChatGPT (Model 5.6) solely to assist with English language editing, grammar, and spelling correction in order to improve clarity and readability. After using this tool, the authors carefully reviewed and revised the manuscript as necessary and take full responsibility for the scientific content, interpretations, and conclusions presented in the published article.

Abbreviations

EAU, European Association of Urology; PCR, polymerase chain reaction.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2020;203(2):351–18. doi: 10.1097/JU.0000000000000509 [DOI] [PubMed] [Google Scholar]
  • 2.World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Geneva: World Health Organization; 2024. [Google Scholar]
  • 3.Sati H, Carrara E, Savoldi A, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2025;25(9):1033–1043. doi: 10.1016/S1473-3099(25)00118-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Brandon H, Montelongo-Jauregui D, Swaminathan N. Mycoplasma hominis prosthetic valve infective endocarditis and endophthalmitis in a renal transplant recipient: a case report. Ther Adv Infect Dis. 2025;12:20499361251357405. doi: 10.1177/20499361251357405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zhang H, Yang L. Ureaplasma urealyticum infection following organ transplantation: a case report and narrative review. Ren Fail. 2024;46(2):2395466. doi: 10.1080/0886022X.2024.2395466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Song J, Wu X, Kong Y, et al. Prevalence and antibiotics resistance of Ureaplasma species and Mycoplasma hominis in Hangzhou, China, from 2013 to 2019. Front Microbiol. 2022;13:982429. doi: 10.3389/fmicb.2022.982429 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gupta RS, Sawnani S, Adeolu M, Alnajar S, Oren A. Phylogenetic framework for the phylum Tenericutes based on genome sequence data: proposal for the creation of a new order Mycoplasmoidales ord. nov. containing two new families Mycoplasmoidaceae fam. nov. and Metamycoplasmataceae fam. nov. harbouring Eperythrozoon, Ureaplasma and five novel genera. Antonie van Leeuwenhoek. 2018;111(9):1583–1630. doi: 10.1007/s10482-018-1047-3 [DOI] [PubMed] [Google Scholar]
  • 8.Taylor-Robinson D. Mollicutes in vaginal microbiology: Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma genitalium. Res Microbiol. 2017;168(9–10):875–881. doi: 10.1016/j.resmic.2017.02.009 [DOI] [PubMed] [Google Scholar]
  • 9.Waites KB, Xiao L, Dybvig K. Mycoplasmas and ureaplasmas. In: Tang YW, Hindiyeh MY, Liu D, Sails A, Spearman P, Zhang JR, editors. Molecular Medical Microbiology, 3rd. Elsevier. 2024; Vol. 2024. 1519–1546. doi: [Google Scholar]
  • 10.Beeton ML, Spiller OB. Antibiotic resistance among Ureaplasma spp. isolates: cause for concern? J Antimicrob Chemother. 2017;72(2):330–337. doi: 10.1093/jac/dkw425 [DOI] [PubMed] [Google Scholar]
  • 11.Waites KB, Bebear CM. Mycoplasma and Ureaplasma In: Carroll KC, Pfaller MA, Karlowsky JA, et al. editors, Manual of Clinical Microbiology. 13th, Washington, DC: ASM Press; 2023. doi: 10.1002/9781683670438.mcm0065 [DOI] [Google Scholar]
  • 12.Farfour E, Vasse M, Vallee A. Mollicutes-related infections in thoracic surgery including lung and heart transplantation: a systematic review. J Heart Lung Transplant. 2024;43(1):169–180. doi: 10.1016/j.healun.2023.09.023 [DOI] [PubMed] [Google Scholar]
  • 13.Bharat A, Cunningham SA, Budinger GRS, et al. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med. 2015;7(284):284re3. doi: 10.1126/scitranslmed.aaa8419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lee JY, Yang JS. Prevalence and antimicrobial susceptibility of Mycoplasma hominis and Ureaplasma species in nonpregnant female patients in South Korea indicate an increasing trend of pristinamycin-resistant isolates. Antimicrob Agents Chemother. 2020;64(10):e01065–20. doi: 10.1128/AAC.01065-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Garcia-Castillo M, Morosini MI, Galvez M, Baquero F, Del Campo R, Meseguer MA. Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J Antimicrob Chemother. 2008;62(5):1027–1030. doi: 10.1093/jac/dkn337 [DOI] [PubMed] [Google Scholar]
  • 16.Kitagawa H, Shimizu H, Katayama K, et al. Postoperative mediastinitis after cardiac surgery caused by Mycoplasma hominis: a case report. Surg Case Rep. 2021;7(1):248. doi: 10.1186/s40792-021-01326-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gerber L, Gaspert A, Braghetti A, et al. Ureaplasma and Mycoplasma in kidney allograft recipients: a case series and review of the literature. Transpl Infect Dis. 2018;20(5):e12937. doi: 10.1111/tid.12937 [DOI] [PubMed] [Google Scholar]
  • 18.Bai X, Sang Y, Ke L, et al. Head trauma complicated with multi-site infections of Ureaplasma urealyticum and Mycoplasma hominis: a case report. BMC Infect Dis. 2026;26(1):64. doi: 10.1186/s12879-025-12314-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cai S, Pan J, Wang S, et al. Accurate etiological diagnosis of Mycoplasma hominis mediastinitis in immunocompetent patients using metagenomic next-generation sequencing: a case series and literature review. J Thorac Dis. 2024;16(4):2499–2509. doi: 10.21037/jtd-24-286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Adams M, Bouzigard R, Al-Obaidi M, et al. Perinephric abscess in a renal transplant recipient due to Mycoplasma hominis: case report and review of the literature. Transpl Infect Dis. 2020;22(5):e13308. doi: 10.1111/tid.13308 [DOI] [PubMed] [Google Scholar]
  • 21.Grenabo L, Claes G, Hedelin H, Pettersson S. Rapidly recurrent renal calculi caused by Ureaplasma urealyticum: a case report. J Urol. 1986;135(5):995–997. doi: 10.1016/s0022-5347(17)45953-2 [DOI] [PubMed] [Google Scholar]
  • 22.Pereyre S, Tardy F, Renaudin H, et al. Identification and subtyping of clinically relevant human and ruminant mycoplasmas by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2013;51(10):3314–3323. doi: 10.1128/JCM.01573-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dong Y, He Y, Zhou X, et al. Diagnosis of Mycoplasma hominis meningitis with metagenomic next-generation sequencing: a case report. Infect Drug Resist. 2022;15:4479–4486. doi: 10.2147/IDR.S371771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Deng C, Hong L, Sun D, et al. Diagnosis of Mycoplasma hominis peritonitis in a CAPD patient with metagenomic next-generation sequencing: a case report. Infect Drug Resist. 2025;18:2469–2473. doi: 10.2147/IDR.S510660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Takahashi Y, Sada RM, Matsuo H, et al. Diagnostic challenges in postoperative pelvic infections associated with Metamycoplasma hominis: a two-case analysis using metagenomic sequencing. Front Cell Infect Microbiol. 2026;16:1823299. doi: 10.3389/fcimb.2026.1823299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Razi A, Ghiaei A, Kamali Dolatabadi F, Haghighi R. Unraveling the association of bacteria and urinary stones in patients with urolithiasis: an update review article. Front Med Lausanne. 2024;11:1401808. doi: 10.3389/fmed.2024.1401808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kotait MM, Nourie N, Mouawad S, et al. Ureaplasma urealyticum-encrusted pyelitis in a kidney graft patient: a case report and narrative review on encrusted pyelitis. Transpl Infect Dis. 2022;24(1):e13755. doi: 10.1111/tid.13755 [DOI] [PubMed] [Google Scholar]
  • 28.Nowbakht C, Edwards AR, Rodriguez-Buritica DF, et al. Two cases of fatal hyperammonemia syndrome due to Mycoplasma hominis and Ureaplasma urealyticum in immunocompromised patients outside lung transplant recipients. Open Forum Infect Dis. 2019;6(3):ofz033. doi: 10.1093/ofid/ofz033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Higgins AB, Farmakiotis D, Rogers R, et al. Hyperammonemia syndrome due to Ureaplasma urealyticum in a kidney transplant recipient: a case of disseminated disease from a fluoroquinolone-resistant isolate. Transpl Infect Dis. 2020:22:e13328. doi: 10.1111/tid.13328. [DOI] [PubMed] [Google Scholar]
  • 30.Wigston C, Lavender M, Long R, et al. Mycoplasma and Ureaplasma donor-derived infection and hyperammonemia syndrome in 4 solid organ transplant recipients from a single donor. Open Forum Infect Dis. 2023;10(6):ofad263. doi: 10.1093/ofid/ofad263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Grenabo L, Hedelin H, Pettersson S. Urinary infection stones caused by Ureaplasma urealyticum: a review. Scand J Infect Dis Suppl. 1988;53:46–49. PMID:3047857. [PubMed] [Google Scholar]
  • 32.Mobarak A, Tharwat A. Ureaplasma urealyticum as a causative organism of urinary tract infection stones. J Egypt Public Health Assoc. 1996;71(3–4):309–319. PMID:17217015. [PubMed] [Google Scholar]
  • 33.Jagtap A, Das K, Safadi MF. A rare case of a prostatic abscess secondary to a Mycoplasma hominis infection. Cureus. 2022;14(11):e31491. doi: 10.7759/cureus.31491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yokoyama H, Domen T, Hiragata S, Ogawa T, Matsumoto T, Ishizuka O. Postoperative Mycoplasma hominis infection after robot-assisted laparoscopic radical prostatectomy: a case report. Asian J Endosc Surg. 2016;9(2):146–148. doi: 10.1111/ases.12258 [DOI] [PubMed] [Google Scholar]
  • 35.Brunner H, Weidner W, Schiefer HG. Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis. 1983;147(5):807–813. doi: 10.1093/infdis/147.5.807 [DOI] [PubMed] [Google Scholar]
  • 36.Luo J, Wu X, Gang X, Zhang N, Wang F, Rong C. Mycoplasma hominis and Ureaplasma urealyticum infections after knee arthroplasty: a case report. Medicine (Baltimore). 2022;101(45):e31202. doi: 10.1097/MD.0000000000031202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Smolec D, Aptekorz M, Filipczyk L, et al. The quantitative detection of urogenital mycoplasmas in men with urolithiasis. Pathogens. 2025;14(7):670. doi: 10.3390/pathogens14070670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.European Association of Urology. EAU Guidelines on Urological Infections. In: EAU Guidelines. Edition presented at the EAU Annual Congress, London, United Kingdom; 2026. Arnhem, the Netherlands: EAU Guidelines Office; 2026. ISBN 978-94-92671-32-5. [Google Scholar]
  • 39.Hauner K, Kranz J, Wagenlehner FME, et al. Perioperative and peri-interventional antibiotic prophylaxis in urology: key recommendations from the German interdisciplinary AWMF S3 clinical practice guideline. Urol Int. 2026:1–15. doi: 10.1159/000550029. [DOI] [PubMed] [Google Scholar]
  • 40.Wen X, Sarabi Nobakht M, Yang Y, et al. Tetracyclines resistance in Mycoplasma and Ureaplasma urogenital isolates derived from human: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2023;22(1):83. doi: 10.1186/s12941-023-00628-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Waites JT, Crabb DM, Ratliff AE, Waites KB, Xiao L. Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023. Antimicrob Agents Chemother. 2025;69(6):e01868–24. doi: 10.1128/aac.01868-24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Xiao L, Crabb DM, Duffy LB, et al. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp. Int J Antimicrob Agents. 2011;37(4):377–379. doi: 10.1016/j.ijantimicag.2010.12.012 [DOI] [PubMed] [Google Scholar]
  • 43.Dumke R. Antimicrobial resistance in clinical isolates of Ureaplasma spp. from samples in Germany. Antimicrob Agents Chemother. 2021;65(5):e02342–20. doi: 10.1128/AAC.02342-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Vu LH, Le HHL, Le HH, Nguyen TT, Nguyen VH. Infection Rate and Drug Resistance of Ureaplasma urealyticum and Mycoplasma hominis in Patients With Genital Mycoplasma Infection at the National Hospital of Dermatology and Venereology in Vietnam. Int J Microbiol. 2025;2025(1):4006309. doi: 10.1155/ijm/4006309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Song J, Qiao Y, Kong Y, et al. Frequent topoisomerase IV mutations associated with fluoroquinolone resistance in Ureaplasma species. J Med Microbiol. 2015;64(11):1315–1320. doi: 10.1099/jmm.0.000153 [DOI] [PubMed] [Google Scholar]
  • 46.Zhang H, Zheng L, Zhao J, Ding S, Xia Y. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital. J Med Microbiol. 2019;68(2):206–210. doi: 10.1099/jmm.0.000913 [DOI] [PubMed] [Google Scholar]
  • 47.Wu Y, Majidzadeh N, Li Y, et al. Trends of fluoroquinolones resistance in Mycoplasma and Ureaplasma urogenital isolates: systematic review and meta-analysis. J Glob Antimicrob Resist. 2024;36:13–25. doi: 10.1016/j.jgar.2023.11.007 [DOI] [PubMed] [Google Scholar]
  • 48.Clinical and Laboratory Standards Institute. M43-A: Methods for Antimicrobial Susceptibility Testing of Human Mycoplasmas; Approved Guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. [PubMed] [Google Scholar]
  • 49.Meygret A, Le Roy C, Renaudin H, Bebear C, Pereyre S. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. J Antimicrob Chemother. 2018;73(10):2696–2703. doi: 10.1093/jac/dky238 [DOI] [PubMed] [Google Scholar]
  • 50.Liu Y, Li F, Xie J, et al. Clinical characteristics and antimicrobial management of invasive Mycoplasma hominis infection: a case report and literature review. Front Med Lausanne. 2026;13:1728188. doi: 10.3389/fmed.2026.1728188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Van de Perre E, Reichman G, De Geyter D, Geers C, Wissing KM, Letavernier E. Encrusted uropathy: a comprehensive overview-to the bottom of the crust. Front Med Lausanne. 2020;7:609024. doi: 10.3389/fmed.2020.609024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Vijayvargiya P, Esquer Garrigos Z, Kennedy CC, et al. Routine donor and recipient screening for Mycoplasma hominis and Ureaplasma species in lung transplant recipients. Open Forum Infect Dis. 2022;9(11):ofac607. doi: 10.1093/ofid/ofac607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Riva CG, Cacciola R, Cusumano G, et al. Early onset Mycoplasma spp. infection after kidney transplantation: a systematic review. Clin Transplant. 2025;39(10):e70262. doi: 10.1111/ctr.70262 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Drug Resistance are provided here courtesy of Dove Press

RESOURCES